• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Dexcom G6 CGMs win reimbursement coverage in Japan

December 1, 2022 By Sean Whooley

Dexcom G6
The G6 platform. [Image from Dexcom]
Terumo announced today that the Japanese medical insurance system expanded reimbursement coverage for the Dexcom G6 CGM.

Japan’s medical insurance system introduced a new category titled “C150.” It makes a wider range of people with diabetes eligible to receive reimbursement for the Dexcom G6 continuous glucose monitor (CGM) in Japan.

Dexcom develops and manufactures the current-generation G6 CGM. It offers the next-generation Dexcom G7 CGM in the UK, Ireland, Germany, Austria and Hong Kong. U.S. approval could come soon, too. Terumo markets the G6 in Japan, according to a news release.

The Dexcom G6 system features a wearable sensor attached to a user’s abdomen. It automatically transmits glucose measurements every five minutes to a monitor or smart device with a dedicated application. Users can check their real-time glucose values and trends through a visualized graph.

Additionally, G6 notifies users when glucose measurements fall outside a pre-set target range. It also sends alerts upon predictions of hypoglycemia occurring in 20 minutes.

The platform previously held coverage in two reimbursement categories. Those categories limited eligibility to a person with type 1 diabetes or a person with type 2 diabetes with the conditions of unstable glycemic control. It required hospitals to apply for eligibility to prescribe the Dexcom G6 and receive reimbursement. Only facilities meeting a specific criteria could apply.

Japan’s new C150 category covers all people who undergo insulin self-injection at least once per day. Coverage extends to all who fall into this category, regardless of their type of diabetes. Hospitals no longer need to submit for eligibility under the Japanese medical insurance program. Under the new category, all hospitals have eligibility to receive reimbursement.

Filed Under: Business/Financial News, Diabetes, Drug-Device Combinations, Featured, Patient Monitoring, Technology

IN CASE YOU MISSED IT

  • BD files patent infringement lawsuit against Baxter over infusion pump tech
  • Tandem Diabetes Care subsidiary earns new FDA clearance for insulin infusion set
  • Glucotrack can proceed with long-term glucose monitor study in Australia
  • Dexcom promotes Jake Leach to president role
  • Roche invests $550M to make Indianapolis a CGM manufacturing hub

About Sean Whooley

Sean Whooley is an associate editor who mainly produces work for MassDevice, Medical Design & Outsourcing and Drug Delivery Business News. He received a bachelor's degree in multiplatform journalism from the University of Maryland, College Park. You can connect with him on LinkedIn or email him at swhooley@wtwhmedia.com.

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS